 80% of patients in all cohorts (SP, SP + max LLT, SP + max LLT + T2D) were eligible for apheresis at baseline (LDL-C ≥100 mg/dL)  Applying LAPLACE-2 efficacy regarding predicted LDL-C reduction ( Figure 1)  100% of patients in all cohorts can possibly avoid apheresis by reaching recommended LDL-C levels < 100 mg/dL  99% in all cohorts reached target according to ESC-guideline (LDL-C levels < 70 mg/d)  Applying DESCARTES efficacy regarding predicted LDL-C reduction (Figure 2)  99% of patients in all cohorts can possibly avoid apheresis by reaching recommended LDL-C levels < 100 mg/dL  81%, 84%, and 88% reached target according to ESC-guideline (LDL-C levels < 70 mg/dL) in the SP, the SP + max LLT, and the SP + max LLT + T2D cohort respectively
INTRODUCTION
 Secondary prevention patients already on maximally tolerated lipid lowering therapy (LLT) and not achieving their LDL-C target levels would qualify for apheresis as the last option for further LDL-C lowering.  The estimated number of patients who are eligible for apheresis in Germany largely exceeds the number of patients currently on apheresis.  With approximately € 40.000 annual treatment costs per patient, use of apheresis is restricted by having a lengthy and complex approval process 1  According to German authorities, apheresis-treatment is an invasive, burdensome procedure and therefore only applied as "ultima ratio" for high-risk patients with hypercholesterolemia .2
OBJECTIVES
Evaluate the potency of evolocumab*, an innovative new lipid-lowering agent inhibiting PCSK9, to avoid apheresis treatment in patients who meet the requirements for apheresis eligibility in Germany.
*European marketing authorization has been applied for; evolocumab is still not available on the market.
METHODS
 Individual patient-profiles were derived from the IMS ® DA database (2011-2013)  Efficacy from two evolocumab trials (DESCARTES 3 and LAPLACE-2 4 ) were applied in this model*  Mean reduction from baseline ranged from 59.3% (95% CI [54.9%, 63.8%]) in DESCARTES** to 72.3% (95% CI [69.1%, 75.4%]) in LAPLACE-2***  Efficacy was applied to baseline LDL-C levels of the identified patient-profiles using a probabilistic approach  The treatment goal in patients with hypercholesterolemia at high risk for CVE is LDL-C <100 mg/dL according to the German AKdÄ-guideline 5  Sensitivity-analysis were conducted for LDL-C treatment goal according to ESC (T2D) and/or chronic kidney disease (CKD), or none of those two diagnoses AND  Patients were to receive no treatment, low dose statin or max LLT**** for hypercholesterolemia  Apheresis eligibility was assumed in high-risk patients with baseline LDL-C levels ≥ 100 mg/dL Exclusion Criteria  Patients with homozygous familial hypercholesterolemia *placebo-adjusted estimates were applied; picture does not change by using the non-placebo-adjusted ones; **DESCARTES: 52-weeks, placebo controlled phase III trial on long-term safety and efficacy of evolocumab; ***LAPLACE-2: 12-weeks, actively controlled phase III trial on LDL-C reduction with evolocumab as an add-on to statins and/or ezetimibe; **** high dose statins or combination therapy 
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CONCLUSIONS
 Predicted LDL-C lowering based on the efficacy from two evolocumab trials indicated a possible avoidance of apheresis.  For high-risk, secondary prevention patients already on maximally tolerated lipid-lowering therapy and still not reaching LDL-C target levels, evolocumab may offer an additional treatment solution before applying for apheresis  The use of evolocumab could avoid apheresis in high risk, secondary prevention patients who are currently treated as well as in patients eligible for apheresis  Apheresis is a burdensome and costly procedure and its avoidance utilizing evolocmab could potentially reduce patient's burden and provide significant savings to the German healthcare system  Real-life data is needed to prove this concept, once evolocumab is available on the German market. 
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